Quest Diagnostics Files 8-K on Financials

TL;DR

Quest Diagnostics dropped an 8-K on July 22nd detailing their financial results. Check it out.

AI Summary

Quest Diagnostics Inc. filed an 8-K on July 22, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, incorporated in Delaware, is headquartered at 500 Plaza Drive, Secaucus, NJ 07094.

Why It Matters

This filing provides an update on Quest Diagnostics' financial performance and operational results, which is crucial for investors to assess the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing and does not indicate any unusual risks or events.

Key Players & Entities

• Quest Diagnostics Inc. (company) — Registrant
• July 22, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• 500 Plaza Drive (address) — Principal executive offices
• Secaucus, NJ (location) — City and State of principal executive offices
• 07094 (zip_code) — Zip code of principal executive offices
• 001-12215 (filing_number) — Commission File Number
• 16-1387862 (ein) — I.R.S. Employer Identification No.

FAQ

From the Filing

0001022079-25-000172.txt : 20250722 0001022079-25-000172.hdr.sgml : 20250722 20250722064839 ACCESSION NUMBER: 0001022079-25-000172 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250722 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250722 DATE AS OF CHANGE: 20250722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 251138647 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx-20250722.htm 8-K dgx-20250722 0001022079 false 0001022079 2025-07-22 2025-07-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) : July 22, 2025 Quest Diagnostics Inc orporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.) 500 Plaza Drive Secaucus, NJ 07094 (Address of principal executive offices) (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition On July 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.      Item 9.01. Financial Statements and Exhibits d. Exhibit 99.1 Press release of Quest Diagnostics Incorporated dated July 22, 2025, announcing, among other things, its results for the quarter ended June 30, 2025. 104 The cover page from this current report on Form 8-K, formatted in Inline XBRL. Signature      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by th